Skip to content
10-K

Annual Report

VIKING THERAPEUTICS, INC. VKTX

0000950170-25-027824

← back to feed
Filed
Feb 26, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Jan 31, 2025 112.25M sh
Cash And Equivalents FY 2024 · Dec 31, 2023 $55.52M
Stockholders Equity FY 2024 · Dec 31, 2023 $348.42M
Current Liabilities FY 2024 · Dec 31, 2023 $19.14M
Total Liabilities FY 2024 · Dec 31, 2023 $20.07M
Current Assets FY 2024 · Dec 31, 2023 $367.23M
Total Assets FY 2024 · Dec 31, 2023 $368.49M
Shares Diluted FY 2024 · Dec 31, 2022 76.83M sh
Stock Repurchased FY 2024 · Dec 31, 2022 $6.8M
Operating Cash Flow FY 2024 · Dec 31, 2022 −$48.4M
Eps Diluted FY 2024 · Dec 31, 2022 −$0.90
Eps Basic FY 2024 · Dec 31, 2022 −$0.90
Sga Expense FY 2024 · Dec 31, 2022 $16.12M
Rd Expense FY 2024 · Dec 31, 2022 $54.23M
Net Income FY 2024 · Dec 31, 2022 −$68.87M
Operating Income FY 2024 · Dec 31, 2022 −$70.36M
Revenue FY 2024 · Dec 31, 2022 $0